<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04428281</url>
  </required_header>
  <id_info>
    <org_study_id>BP41674</org_study_id>
    <secondary_id>2019-003787-48</secondary_id>
    <secondary_id>RG6091</secondary_id>
    <nct_id>NCT04428281</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome</brief_title>
  <official_title>An Open-Label, Multicenter Study To Investigate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of RO7248824 In Participants With Angelman Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, multicenter, non-randomized, adaptive, open label, multiple ascending,&#xD;
      intra-participant, dose-escalation study using IT administration to investigate the safety,&#xD;
      tolerability, PK and PD of RO7248824 in participants with AS.&#xD;
&#xD;
      Two linked sets of dose escalation cohorts are planned based on two different age groups,&#xD;
      namely participants with AS aged ≥ 5 to ≤ 12 years in cohorts A1 to A4 (with at least 2&#xD;
      participants ≤ 8 years old in each cohort) and AS participants aged ≥ 1 to ≤ 4 years in&#xD;
      cohorts B1 to B5. The two sets of cohorts will be run in parallel, with each cohort A1-A4&#xD;
      preceding and gating the linked cohort B1-B5 (e.g., A1 precedes B1).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">September 13, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 13, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non-randomized, adaptive, open label, multiple ascending, intra-participant, dose-escalation study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency And Severity Of Adverse Events</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency And Severity Of Serious Adverse Events</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Discontinued Treatment due to Adverse Events</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency Of Abnormal Laboratory Findings (Blood And Cerebrospinal Fluid [CSF])</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency Of Abnormal Vital Signs</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency Of Abnormal ECG Values</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Changes From Baseline in Temperature Over Time</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Changes From Baseline in Systolic Blood Pressure Over Time</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Changes From Baseline In Diastolic Blood Pressure Over Time</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Changes From Baseline In Heartrate Over Time</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Changes From Baseline In Respiratory Rate Over Time</measure>
    <time_frame>Baseline to last visit (Day 365) or early withdrawal</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) for RO7248824</measure>
    <time_frame>Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration Observed (Cmax) for RO7248824</measure>
    <time_frame>Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time 0 To Time Of Last Sampling Point Or Last Quantifiable Sample, Whichever Comes First (AUC last) for RO7248824</measure>
    <time_frame>Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC From Time 0 To Infinity (AUCinf) for RO7248824</measure>
    <time_frame>Day 1, 2, 15, 29, 30, 42, 56, 57, 70, 100, 224, 365 or early withdrawal</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Angelman Syndrome</condition>
  <arm_group>
    <arm_group_label>Cohort A1 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-12 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A2 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-12 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A3 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-12 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A4 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-12 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort A5 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 5-12 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B1 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B4 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B5 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B6 RO7248824</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 1-4 Years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO7248824</intervention_name>
    <description>RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 weeks between each dose administration.</description>
    <arm_group_label>Cohort A1 RO7248824</arm_group_label>
    <arm_group_label>Cohort A2 RO7248824</arm_group_label>
    <arm_group_label>Cohort A3 RO7248824</arm_group_label>
    <arm_group_label>Cohort A4 RO7248824</arm_group_label>
    <arm_group_label>Cohort A5 RO7248824</arm_group_label>
    <arm_group_label>Cohort B1 RO7248824</arm_group_label>
    <arm_group_label>Cohort B2 RO7248824</arm_group_label>
    <arm_group_label>Cohort B3 RO7248824</arm_group_label>
    <arm_group_label>Cohort B4 RO7248824</arm_group_label>
    <arm_group_label>Cohort B5 RO7248824</arm_group_label>
    <arm_group_label>Cohort B6 RO7248824</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant has a parent, caregiver or legal representative (hereinafter&#xD;
             &quot;caregiver&quot;) who is reliable, competent and at least 18 years of age. The caregiver is&#xD;
             willing and able to accompany the participant to clinic visits and to be available to&#xD;
             the Investigational Site by phone or email if needed and who (in the opinion of the&#xD;
             investigator) is and will remain sufficiently knowledgeable of participant's ongoing&#xD;
             condition to respond to any inquiries about the participant from personnel from the&#xD;
             Study Site.&#xD;
&#xD;
          -  A caregiver must be able to consent for the participant according to International&#xD;
             Council on Harmonisation (ICH) and local regulations.&#xD;
&#xD;
          -  Ability to comply with all study requirements.&#xD;
&#xD;
          -  Have adequate supportive psychosocial circumstances.&#xD;
&#xD;
          -  Able to tolerate blood draws.&#xD;
&#xD;
          -  Able to undergo LP and IT injection, under sedation or anesthesia if needed and as&#xD;
             determined appropriate by the Investigator.&#xD;
&#xD;
          -  Stable medical status for at least 4 weeks prior to Screening and at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  Body weight of ≥ 7 kg&#xD;
&#xD;
          -  Participant must be ≥ 1 to ≤ 12 years of age at the time of signing of the informed&#xD;
             consent by the caregiver.&#xD;
&#xD;
          -  Clinical diagnosis of AS confirmed by a molecular diagnosis with genotypic&#xD;
             classification of either UBE3A mutation of the maternal allele or deletion on the&#xD;
             maternally inherited chromosome 15q11q13 that includes the UBE3A gene and is less than&#xD;
             7 Mb in size.&#xD;
&#xD;
        Reproductive Status:&#xD;
&#xD;
        Some of the provisions that follow may have limited applicability based on the age range of&#xD;
        study participants (i.e., up to the age of 12) and the nature of the disease understudy.&#xD;
        These provisions are nonetheless included for purposes of completeness in order:&#xD;
&#xD;
        Female Participants&#xD;
&#xD;
        A female participant is eligible to participate if she is not pregnant, not breastfeeding,&#xD;
        and at least one of the following conditions applies:&#xD;
&#xD;
          -  Women of non-childbearing potential.&#xD;
&#xD;
          -  Women of childbearing potential who agree to remain abstinent (refrain from&#xD;
             heterosexual intercourse) or use acceptable contraceptive methods during the treatment&#xD;
             period and for at least 6 months after the final dose of RO7248824 (RG6091). The&#xD;
             following are acceptable contraceptive methods: bilateral tubal occlusion/ ligation,&#xD;
             male sexual partner who is sterilized, established proper use of hormonal&#xD;
             contraceptives that inhibit ovulation, hormone-releasing intrauterine devices and&#xD;
             copper intrauterine devices, male or female condom with or without spermicide; and&#xD;
             cap, diaphragm, or sponge with spermicide.&#xD;
&#xD;
        Male Participants&#xD;
&#xD;
        During the treatment period and for at least 6 months after the final dose of RO7248824&#xD;
        (RG6091), consent has to be provided to:&#xD;
&#xD;
          -  Remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures&#xD;
             such as a condom, with a female partner of childbearing potential, or pregnant female&#xD;
             partner, to avoid exposing the embryo.&#xD;
&#xD;
        The reliability of sexual abstinence for male and/or female enrollment eligibility needs to&#xD;
        be evaluated in relation to the duration of the clinical study and the preferred and usual&#xD;
        lifestyle of the participant. Periodic abstinence (e.g., calendar, ovulation,&#xD;
        symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of&#xD;
        preventing drug exposure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Diagnostic Assessments&#xD;
&#xD;
          -  Clinically-significant laboratory, vital sign or electrocardiography (ECG)&#xD;
             abnormalities at Screening&#xD;
&#xD;
        Type of Participants and Disease Characteristics&#xD;
&#xD;
          -  Molecular diagnosis of AS with genotypic classification:&#xD;
&#xD;
        UBE3A missense mutation of maternal allele Paternal Uniparental Disomy (UPD) of 15q11-13&#xD;
        UBE3A Imprinting center defect (ID) A partial molecular diagnosis of AS, that cannot&#xD;
        exclude UPD or ID despite appropriate genetic testing.&#xD;
&#xD;
        Medical history and concurrent disease&#xD;
&#xD;
          -  Clinically relevant hematological, hepatic, cardiac or renal disease or event, in the&#xD;
             judgement of the investigator. Pre-existing abnormal hepatic, renal or hematology lab&#xD;
             tests must be discussed with the Sponsor Medical Monitor.&#xD;
&#xD;
          -  Any concomitant condition that might interfere with the clinical evaluation of AS and&#xD;
             that is not related to AS.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) or hepatitis B virus (HBV) or&#xD;
             hepatitis C virus (HCV).&#xD;
&#xD;
          -  Any condition that increases risk of meningitis.&#xD;
&#xD;
          -  History of bleeding diathesis or coagulopathy.&#xD;
&#xD;
          -  A medical history of brain or spinal disease that would interfere with the LP process,&#xD;
             cerebrospinal fluid (CSF) circulation or safety assessment&#xD;
&#xD;
          -  History of clinically significant post-lumbar-puncture headache of moderate or severe&#xD;
             intensity and/or blood patch&#xD;
&#xD;
          -  Malignancy within 5 years of Screening&#xD;
&#xD;
          -  Hospitalization for any major medical or surgical procedure involving general&#xD;
             anesthesia within 12 weeks of Screening or planned during the study&#xD;
&#xD;
          -  Have any other conditions, which, in the opinion of the Investigator, would make the&#xD;
             participant unsuitable for inclusion or could interfere with the participant&#xD;
             participating in or completing the study, including any contraindication to&#xD;
             administration of intrathecal therapy.&#xD;
&#xD;
          -  Premature birth with gestational age at birth below 34 weeks.&#xD;
&#xD;
          -  History of hypersensitivity to the investigational medicinal product (IMP), antisense&#xD;
             oligonucleotides, or any excipients.&#xD;
&#xD;
        Prior Therapy&#xD;
&#xD;
          -  Allowed sleep medications have not been stable for 4 weeks prior to screening and at&#xD;
             the time of enrollement.&#xD;
&#xD;
          -  Allowed medications for treatment of epilepsy have not been stable for 12 weeks prior&#xD;
             to screening and at the time of enrollment.&#xD;
&#xD;
          -  Use of antiplatelet or anticoagulant therapy for 2 weeks prior to screening and at the&#xD;
             time of enrollment.&#xD;
&#xD;
          -  Concurrent psychotropic medications have not been stable for 4 weeks prior to&#xD;
             screening and at the time of enrollment.&#xD;
&#xD;
        Other Exclusion Criteria: Prior/Concurrent Clinical Study Experience&#xD;
&#xD;
          -  Received an investigational drug within 90 days or 5 times the half-life of the&#xD;
             investigational drug (whichever is longer) or participation in a study testing an&#xD;
             investigational medical device within 90 days prior to first dosing or if the device&#xD;
             is still active.&#xD;
&#xD;
          -  Concurrent or planned concurrent participation in any clinical study (including&#xD;
             observational and non-interventional studies) without approval of the Sponsor Medical&#xD;
             Monitor. At the discretion of the Sponsor, participants may enroll into non-drug&#xD;
             observational studies.&#xD;
&#xD;
          -  Previous participation in a cellular therapy, or gene therapy, or gene editing&#xD;
             clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: BP41674 https://forpatients.roche.com/</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global-roche-genentech-trials@gene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA Neuropsychiatric Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rady Children's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rush Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Carolina Institute for Development Disabilities University of North Carolina/School of Medicine</name>
      <address>
        <city>Carrboro</city>
        <state>North Carolina</state>
        <zip>27510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Baylor College of Med; Texas Child Hosp; Pediactric Dept</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Bambino Gesù; Dip. Neuroscienze e Neuroriabilitazione</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus MC / location Sophia Kinderziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu; Neurologia Pediatrica</name>
      <address>
        <city>Esplugues De Llobregat · Barcelona</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Corporacio Sanitaria Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <state>Barcelona</state>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío; Servicio de Neuropediatra</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 9, 2020</study_first_submitted>
  <study_first_submitted_qc>June 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2020</study_first_posted>
  <last_update_submitted>November 9, 2021</last_update_submitted>
  <last_update_submitted_qc>November 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RO7248824; Angelman; ASO; LNA; Angelman syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Angelman Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

